XML 35 R18.htm IDEA: XBRL DOCUMENT v3.19.1
Fair Value Measurements
3 Months Ended
Mar. 29, 2019
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS
The classification within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis was as follows (in thousands):
 
March 31, 2019
 
Level 1
 
Level 2
 
Total
Money market funds
$
75,171

 
$

 
$
75,171

Commercial paper

 
414,317

 
414,317

Corporate bonds

 
418,385

 
418,385

U.S. Treasury and government sponsored enterprises

 
84,487

 
84,487

Total investments available-for-sale
75,171

 
917,189

 
992,360

Certificates of deposit

 
25,990

 
25,990

Total financial assets carried at fair value
$
75,171

 
$
943,179

 
$
1,018,350

 
December 31, 2018
 
Level 1
 
Level 2
 
Total
Money market funds
$
47,744

 
$

 
$
47,744

Commercial paper

 
381,133

 
381,133

Corporate bonds

 
344,064

 
344,064

U.S. Treasury and government sponsored enterprises

 
55,201

 
55,201

Total investments available-for-sale
47,744

 
780,398

 
828,142

Certificates of deposit

 
16,596

 
16,596

Total financial assets carried at fair value
$
47,744

 
$
796,994

 
$
844,738


We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of March 31, 2019 or December 31, 2018. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of March 31, 2019 or December 31, 2018. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the three months ended March 31, 2019 or 2018.
When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.
See “Note 11. Commitments” to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 for a description of the determination of the amount of our operating lease liabilities. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities, Rebates and fees due to customers and other current and long-term liabilities. Those financial assets and liabilities are carried at cost which approximates their fair values.